New combination therapy offers bowel cancer patients extra treatment option


Based on scientific findings of the Netherlands Cancer Institute a new combination treatment has been developed for patients with metastatic bowel cancer and a mutation in the BRAF gene. The results of a clinical trial in over 600 patients have revealed that patients treated with this smart combination therapy survive longer than those who have standard treatment. The study is published today in The New England Journal of Medicine.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.